Fulgent Genetics Inc. Publishes Transcript of Q3 2025 Earnings Call

Reuters

2025/12/09

<a href="https://laohu8.com/S/FLGT">Fulgent Genetics Inc.</a> Publishes Transcript of Q3 2025 Earnings Call

Fulgent Genetics Inc. has published the corrected transcript of its Q3 2025 earnings call, held on November 7, 2025. The event featured key company executives, including Chairman, Chief Executive Officer & Founder Ming Hsieh, Chief Commercial Officer Brandon Perthuis, and Chief Financial Officer Paul H. Kim. Analysts from UBS Securities, Piper Sandler & Co., and Raymond James Financial also participated. During the call, management provided an overview of the company's third quarter performance, discussing updates on both their core business lines and laboratory services. The CEO commented, "I will start with some comments on the third quarter of 2025 and our two business lines," indicating a focus on operational progress. Updates on product development and go-to-market strategies were reviewed, as well as detailed financial results and forward-looking guidance. Management also highlighted the risks and uncertainties associated with forward-looking statements, emphasizing that actual results could differ due to changing circumstances. The full transcript can be accessed through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fulgent Genetics Inc. published the original content used to generate this news brief on December 08, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2590282363"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2590282363\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2590282363?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-09 04:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2590282363","market":"nz","top_or_hot":-1,"title":"Fulgent Genetics Inc. Publishes Transcript of Q3 2025 Earnings Call","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/FLGT\">Fulgent Genetics Inc.</a> Publishes Transcript of Q3 2025 Earnings Call\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Fulgent Genetics Inc. has published the corrected transcript of its Q3 2025 earnings call, held on November 7, 2025. The event featured key company executives, including Chairman, Chief Executive Officer &amp; Founder Ming Hsieh, Chief Commercial Officer Brandon Perthuis, and Chief Financial Officer Paul H. Kim. Analysts from UBS Securities, Piper Sandler &amp; Co., and Raymond James Financial also participated. During the call, management provided an overview of the company's third quarter performance, discussing updates on both their core business lines and laboratory services. The CEO commented, \"I will start with some comments on the third quarter of 2025 and our two business lines,\" indicating a focus on operational progress. Updates on product development and go-to-market strategies were reviewed, as well as detailed financial results and forward-looking guidance. Management also highlighted the risks and uncertainties associated with forward-looking statements, emphasizing that actual results could differ due to changing circumstances. The full transcript can be accessed through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fulgent Genetics Inc. published the original content used to generate this news brief on December 08, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Fulgent Genetics Inc. Publishes Transcript of Q3 2025 Earnings Call</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFulgent Genetics Inc. Publishes Transcript of Q3 2025 Earnings Call\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-09 04:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/FLGT\">Fulgent Genetics Inc.</a> Publishes Transcript of Q3 2025 Earnings Call\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Fulgent Genetics Inc. has published the corrected transcript of its Q3 2025 earnings call, held on November 7, 2025. The event featured key company executives, including Chairman, Chief Executive Officer &amp; Founder Ming Hsieh, Chief Commercial Officer Brandon Perthuis, and Chief Financial Officer Paul H. Kim. Analysts from UBS Securities, Piper Sandler &amp; Co., and Raymond James Financial also participated. During the call, management provided an overview of the company's third quarter performance, discussing updates on both their core business lines and laboratory services. The CEO commented, \"I will start with some comments on the third quarter of 2025 and our two business lines,\" indicating a focus on operational progress. Updates on product development and go-to-market strategies were reviewed, as well as detailed financial results and forward-looking guidance. Management also highlighted the risks and uncertainties associated with forward-looking statements, emphasizing that actual results could differ due to changing circumstances. The full transcript can be accessed through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fulgent Genetics Inc. published the original content used to generate this news brief on December 08, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nNDL3PVDxx:1","article_id":"2590282363","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2590282363","pubTimestamp":1765225943,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Fulgent Genetics Inc. has published the corrected transcript of its Q3 2025 earnings call, held on November 7, 2025. The event featured key company executives, including Chairman, Chief Executive Officer & Founder Ming Hsieh, Chief Commercial Officer Brandon Perthuis, and Chief Financial Officer Paul H. Kim. Analysts from UBS Securities, Piper Sandler & Co., and Raymond James Financial also participated. During the call, management provided an overview of the company's third quarter performance, discussing updates on both their core business lines and laboratory services. The CEO commented, \"I will start with some comments on the third quarter of 2025 and our two business lines,\" indicating a focus on operational progress. Updates on product development and go-to-market strategies were reviewed, as well as detailed financial results and forward-looking guidance. Management also highlighted the risks and uncertainties associated with forward-looking statements, emphasizing that actual r","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","RJF":"瑞杰金融","LU1363072403.SGD":"Fidelity Global Financial Services A-ACC-SGD","BK4585":"ETF&股票定投概念","BK4196":"保健护理服务","PIPR":"派杰投资","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","FLGT":"Fulgent Genetics Inc.","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU2265009873.SGD":"Eastspring Investments - Global Growth Equity AS SGD-H","LU0971096721.USD":"富达环球金融服务 A","LU1804176565.USD":"EASTSPRING INV GLOBAL GROWTH EQUITY \"A\" (USD) ACC","BK4127":"投资银行业与经纪业","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC"},"translate_title":"Fulgent Genetics Inc.发布2025年第三季度收益看涨期权记录","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RJF":0.9,"FLGT":0.9,"PIPR":0.9},"content_text":"Fulgent Genetics Inc. Publishes Transcript of Q3 2025 Earnings Call\n    \n\n        Fulgent Genetics Inc. has published the corrected transcript of its Q3 2025 earnings call, held on November 7, 2025. The event featured key company executives, including Chairman, Chief Executive Officer & Founder Ming Hsieh, Chief Commercial Officer Brandon Perthuis, and Chief Financial Officer Paul H. Kim. Analysts from UBS Securities, Piper Sandler & Co., and Raymond James Financial also participated. During the call, management provided an overview of the company's third quarter performance, discussing updates on both their core business lines and laboratory services. The CEO commented, \"I will start with some comments on the third quarter of 2025 and our two business lines,\" indicating a focus on operational progress. Updates on product development and go-to-market strategies were reviewed, as well as detailed financial results and forward-looking guidance. Management also highlighted the risks and uncertainties associated with forward-looking statements, emphasizing that actual results could differ due to changing circumstances. The full transcript can be accessed through the link below.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fulgent Genetics Inc. published the original content used to generate this news brief on December 08, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}